Core Insights - Bavarian Nordic has entered into a manufacturing agreement with Serum Institute of India (SII) to enhance the production capacity of its chikungunya vaccine (CHIKV VLP) for low- and middle-income countries [1][2] - The new agreement builds on an existing partnership for the mpox vaccine and replaces a previous deal with Biological E, with both companies exploring co-development opportunities [2][3] Vaccine Details - The CHIKV VLP vaccine is a prefilled, single-dose, adjuvanted virus-like particle recombinant protein product intended for immunization against chikungunya virus in individuals aged 12 and above [3][4] - The vaccine is designed to elicit a strong seroresponse, with protective immunity developing within one week post-vaccination, and is non-infectious due to the absence of viral genetic material [4] Regulatory and Market Developments - The CHIKV VLP vaccine, marketed as Vimkunya, has received approvals from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission, and the US FDA in 2025 [4] - Regulatory reviews are currently ongoing in Canada and Switzerland, with the vaccine launched in the UK in September 2025 following a 170% increase in travel-related chikungunya cases reported in August 2025 compared to the same month in 2024 [5]